|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Adverum Biotechnologies, Inc (AAVL) |
|
|
$14.95 0.00 (0.00%) as of 4:30 Mon 3/25
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
435,170,000 |
Market
Cap: |
6.51(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.75 - $16.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
230,000 |
230,000 |
330,000 |
456,925 |
Total Buy Value |
$310,500 |
$310,500 |
$455,990 |
$576,247 |
Total People Bought |
2 |
2 |
3 |
9 |
Total Buy Transactions |
2 |
2 |
3 |
10 |
Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
Total People Sold |
0 |
0 |
1 |
5 |
Total Sell Transactions |
0 |
0 |
1 |
9 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Riley Brigit |
Chief Scientific OfficerOffice |
|
2021-09-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
120,000 |
|
-37% |
|
Fischer Laurent |
CEO, President and Director |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
680,000 |
706,292 |
|
- |
|
Clark Julie |
Chief Medical Officer |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
169,489 |
|
- |
|
Thedinga Angela |
Chief Technology Officer |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
Soparkar Peter |
See Remarks section |
|
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
220,000 |
230,692 |
|
- |
|
Clark Julie |
Chief Medical OfficerOfficer |
|
2021-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,489 |
|
-41% |
|
Graham Dawn |
Director |
|
2021-03-31 |
4 |
B |
$10.02 |
$200,338 |
D/D |
20,000 |
20,000 |
2.39 |
-75% |
|
Machado Clarence Patrick |
Director |
|
2021-03-24 |
4 |
B |
$9.92 |
$99,196 |
D/D |
10,000 |
88,182 |
2.39 |
-75% |
|
Fischer Laurent |
CEO and Director |
|
2021-03-24 |
4 |
B |
$9.88 |
$98,780 |
D/D |
10,000 |
26,292 |
2.81 |
-75% |
|
Patterson Leone D |
President and CFO |
|
2021-02-09 |
4 |
S |
$14.10 |
$176,718 |
D/D |
(12,533) |
97,955 |
|
74% |
|
Fischer Laurent |
CEO and Director |
|
2021-01-15 |
4 |
B |
$11.53 |
$99,191 |
D/D |
8,600 |
16,292 |
2.81 |
-69% |
|
Machado Clarence Patrick |
Director |
|
2021-01-15 |
4 |
B |
$11.52 |
$115,174 |
D/D |
10,000 |
78,182 |
2.39 |
-69% |
|
Woiwode Thomas |
Director |
|
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
12,783 |
18,822 |
|
- |
|
Fischer Laurent |
CEO and Director |
|
2020-08-17 |
4 |
B |
$13.00 |
$99,996 |
D/D |
7,692 |
7,692 |
2.81 |
-13% |
|
Soparkar Peter |
Chief Legal Officer |
|
2020-08-17 |
4 |
B |
$13.00 |
$99,996 |
D/D |
7,692 |
10,692 |
2.74 |
-13% |
|
Gasmi Mehdi |
Director |
|
2020-07-20 |
4 |
AS |
$17.60 |
$87,978 |
D/D |
(5,000) |
274,442 |
|
-22% |
|
Gasmi Mehdi |
Director |
|
2020-07-20 |
4 |
OE |
$4.80 |
$24,000 |
D/D |
5,000 |
279,442 |
|
- |
|
Gasmi Mehdi |
Director |
|
2020-06-22 |
4 |
AS |
$25.06 |
$591,617 |
D/D |
(23,605) |
274,442 |
|
-56% |
|
Gasmi Mehdi |
Director |
|
2020-06-22 |
4 |
OE |
$4.80 |
$113,304 |
D/D |
23,605 |
298,047 |
|
- |
|
Gasmi Mehdi |
Director |
|
2020-06-18 |
4 |
AS |
$25.01 |
$278,329 |
D/D |
(11,127) |
274,442 |
|
-54% |
|
Gasmi Mehdi |
Director |
|
2020-06-18 |
4 |
OE |
$4.80 |
$53,410 |
D/D |
11,127 |
285,569 |
|
- |
|
Gasmi Mehdi |
Director |
|
2020-06-17 |
4 |
AS |
$25.01 |
$6,703 |
D/D |
(268) |
274,442 |
|
-53% |
|
Gasmi Mehdi |
Director |
|
2020-06-17 |
4 |
OE |
$4.80 |
$1,286 |
D/D |
268 |
274,710 |
|
- |
|
Patterson Leone D |
President |
|
2020-06-16 |
4 |
S |
$24.68 |
$325,060 |
D/D |
(13,171) |
110,488 |
|
50% |
|
Gasmi Mehdi |
Director |
|
2020-06-15 |
4 |
AS |
$21.01 |
$218,627 |
D/D |
(10,000) |
274,442 |
|
-50% |
|
58 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|